| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
34,860,000 |
| Market
Cap: |
2.09(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$34.28 - $67.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
388,891 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,000,076 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
132,913 |
249,544 |
985,527 |
3,158,237 |
| Total Sell Value |
$7,856,597 |
$14,109,866 |
$54,827,192 |
$182,381,164 |
| Total People Sold |
3 |
6 |
10 |
14 |
| Total Sell Transactions |
13 |
22 |
46 |
88 |
| End Date |
2025-06-15 |
2025-03-14 |
2024-09-13 |
2023-09-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Quisel John D |
Chief Executive Officer |
• • – |
2025-09-09 |
4 |
OE |
$1.01 |
$10,100 |
D/D |
10,000 |
171,828 |
|
- |
|
| Bitterman Kevin |
|
– • – |
2025-08-22 |
4 |
AS |
$61.03 |
$139,576 |
I/I |
(2,287) |
590,621 |
|
-1% |
|
| Bitterman Kevin |
|
– • – |
2025-08-14 |
4 |
AS |
$60.99 |
$439,860 |
I/I |
(7,212) |
592,908 |
|
-1% |
|
| Bitterman Kevin |
|
– • – |
2025-08-13 |
4 |
AS |
$61.15 |
$1,526,426 |
I/I |
(24,962) |
600,120 |
|
-2% |
|
| Bitterman Kevin |
|
– • – |
2025-08-05 |
4 |
AS |
$60.95 |
$24,075 |
I/I |
(395) |
625,082 |
|
-2% |
|
| Bitterman Kevin |
|
– • – |
2025-07-30 |
4 |
AS |
$61.04 |
$518,352 |
I/I |
(8,492) |
625,477 |
|
1% |
|
| Bitterman Kevin |
|
– • – |
2025-07-24 |
4 |
S |
$61.17 |
$797,229 |
I/I |
(13,033) |
633,969 |
|
1% |
|
| Bitterman Kevin |
|
– • – |
2025-07-23 |
4 |
S |
$60.97 |
$1,819,162 |
I/I |
(29,837) |
647,002 |
|
2% |
|
| Bitterman Kevin |
|
– • – |
2025-07-18 |
4 |
S |
$61.13 |
$40,590 |
I/I |
(664) |
676,839 |
|
-4% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2025-07-17 |
4 |
AS |
$59.00 |
$119,829 |
D/D |
(2,031) |
63,499 |
|
4% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2025-07-10 |
4 |
AS |
$57.50 |
$115,000 |
D/D |
(2,000) |
65,530 |
|
3% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-07-09 |
4 |
AS |
$55.23 |
$1,925,525 |
D/D |
(34,800) |
161,828 |
|
7% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-07-09 |
4 |
OE |
$9.86 |
$343,128 |
D/D |
34,800 |
196,628 |
|
- |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-07-03 |
4 |
AS |
$55.09 |
$286,454 |
D/D |
(5,200) |
161,828 |
|
9% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-07-03 |
4 |
OE |
$9.86 |
$51,272 |
D/D |
5,200 |
167,028 |
|
- |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-06-27 |
4 |
OE |
$9.86 |
$316,210 |
D/D |
32,070 |
88,795 |
|
- |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2025-06-16 |
4 |
AS |
$52.26 |
$104,519 |
D/D |
(2,000) |
67,530 |
|
15% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-06-06 |
4 |
AS |
$50.00 |
$149,800 |
D/D |
(2,996) |
56,725 |
|
20% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-05-20 |
4 |
AS |
$50.04 |
$334,128 |
D/D |
(6,677) |
59,721 |
|
19% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-05-02 |
4 |
AS |
$50.17 |
$105,367 |
D/D |
(2,100) |
66,398 |
|
22% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-04-07 |
4 |
OE |
$1.01 |
$7,070 |
D/D |
7,000 |
161,828 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-21 |
4 |
S |
$54.00 |
$540,594 |
I/I |
(10,011) |
187,297 |
|
-14% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-21 |
4 |
S |
$54.00 |
$540,594 |
I/I |
(10,011) |
187,297 |
|
-14% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-20 |
4 |
S |
$54.01 |
$149,176 |
I/I |
(2,762) |
188,617 |
|
-12% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-20 |
4 |
S |
$54.01 |
$149,176 |
I/I |
(2,762) |
188,617 |
|
-12% |
|
201 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.47 (0.78%) 
